Vita Life Sciences Limited, a pharmaceutical and healthcare company, engages in formulation, packaging, distribution, and sale of vitamins and supplements.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$1.55|
|52 Week High||AU$0.84|
|52 Week Low||AU$1.62|
|1 Month Change||26.64%|
|3 Month Change||44.39%|
|1 Year Change||60.94%|
|3 Year Change||60.94%|
|5 Year Change||3.00%|
|Change since IPO||808.82%|
Recent News & Updates
Should You Be Adding Vita Life Sciences (ASX:VLS) To Your Watchlist Today?
Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...
|VLS||AU Pharmaceuticals||AU Market|
Return vs Industry: VLS exceeded the Australian Pharmaceuticals industry which returned -2.4% over the past year.
Return vs Market: VLS exceeded the Australian Market which returned 20.2% over the past year.
Stable Share Price: VLS is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: VLS's weekly volatility (6%) has been stable over the past year.
About the Company
Vita Life Sciences Limited, a pharmaceutical and healthcare company, engages in formulation, packaging, distribution, and sale of vitamins and supplements. It offers a range of supplements, vitamins, minerals, herbs, and superfoods. The company markets its products through pharmacies and health food stores under the Herbs of Gold, VitaHealth, VitaScience, and VitaLife brands.
Vita Life Sciences Fundamentals Summary
|VLS fundamental statistics|
Is VLS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|VLS income statement (TTM)|
|Cost of Revenue||AU$19.20m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.12|
|Net Profit Margin||13.38%|
How did VLS perform over the long term?See historical performance and comparison
3.6%Current Dividend Yield
Is Vita Life Sciences undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: VLS (A$1.55) is trading below our estimate of fair value (A$3.27)
Significantly Below Fair Value: VLS is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: VLS is good value based on its PE Ratio (12.7x) compared to the Oceanic Pharmaceuticals industry average (45x).
PE vs Market: VLS is good value based on its PE Ratio (12.7x) compared to the Australian market (19.8x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate VLS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: VLS is good value based on its PB Ratio (3.1x) compared to the AU Pharmaceuticals industry average (3.3x).
How is Vita Life Sciences forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Vita Life Sciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Vita Life Sciences performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: VLS has high quality earnings.
Growing Profit Margin: VLS's current net profit margins (13.4%) are higher than last year (11.3%).
Past Earnings Growth Analysis
Earnings Trend: VLS's earnings have grown by 13.4% per year over the past 5 years.
Accelerating Growth: VLS's earnings growth over the past year (32.6%) exceeds its 5-year average (13.4% per year).
Earnings vs Industry: VLS earnings growth over the past year (32.6%) exceeded the Pharmaceuticals industry 17.4%.
Return on Equity
High ROE: VLS's Return on Equity (23.9%) is considered high.
How is Vita Life Sciences's financial position?
Financial Position Analysis
Short Term Liabilities: VLS's short term assets (A$30.8M) exceed its short term liabilities (A$13.4M).
Long Term Liabilities: VLS's short term assets (A$30.8M) exceed its long term liabilities (A$388.0K).
Debt to Equity History and Analysis
Debt Level: VLS is debt free.
Reducing Debt: VLS has no debt compared to 5 years ago when its debt to equity ratio was 12%.
Debt Coverage: VLS has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: VLS has no debt, therefore coverage of interest payments is not a concern.
What is Vita Life Sciences's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: VLS's dividend (3.56%) is higher than the bottom 25% of dividend payers in the Australian market (2.27%).
High Dividend: VLS's dividend (3.56%) is low compared to the top 25% of dividend payers in the Australian market (5.32%).
Stability and Growth of Payments
Stable Dividend: VLS's dividend payments have been volatile in the past 10 years.
Growing Dividend: VLS's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (43.1%), VLS's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Andrew O'Keefe has been Managing Director of Vita Life Sciences Limited since January 1, 2017 serves as its Director. Mr. O'Keefe served as Acting Managing Director of Vita Life Sciences Limited since...
CEO Compensation Analysis
Compensation vs Market: Andrew's total compensation ($USD378.53K) is about average for companies of similar size in the Australian market ($USD302.72K).
Compensation vs Earnings: Andrew's compensation has been consistent with company performance over the past year.
Experienced Management: VLS's management team is considered experienced (4.8 years average tenure).
Experienced Board: VLS's board of directors are considered experienced (4.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2%.
Vita Life Sciences Limited's employee growth, exchange listings and data sources
- Name: Vita Life Sciences Limited
- Ticker: VLS
- Exchange: ASX
- Founded: 1947
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$85.265m
- Shares outstanding: 55.19m
- Website: https://www.vitalifesciences.com
- Vita Life Sciences Limited
- Bath Road
- Unit 1/102
- New South Wales
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/18 15:11|
|End of Day Share Price||2021/10/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.